In this Commentary, D. Escors et al discuss the exciting possibility of using systemic CD4 immunity pre‐treatment status as a predictive tool of clinical outcome following PD‐L1/PD‐1 blockade cancer immunotherapy. Here, CD4 is linked to cancer.